Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs,
発行: Roots Analysis
ページ情報: 英文 357 Pages
Targeted Protein Degradation Market:
Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030.
Close to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of development.
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. Owing to various reasons, conventional pharmacological interventions have been severely restricted in terms of accessing protein targets of pathological significance. However, researchers engaged in developing bifunctional protein degrader-based interventions claim that this upcoming class of medicinal compounds possess the capability to access the part of the eukaryotic proteome that was previously considered undruggable. The science behind this innovation revolves around the use of specially designed small molecules that are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target protein, via proteolysis. The applications of this technology in drug discovery are vast. Further, drugs designed / based on this concept are known to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, when compared to traditional occupancy-based inhibitors. As a result, targeted protein degradation-based therapeutics have generated enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of these molecules is evident across modern scientific literature (500+ related articles on NCBI's PubMed portal), and from social media chatter (4,000+ tweets posted on the platform, Twitter, over the last three years).
The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Over the years, significant progress has been made towards understanding the physiochemical and biological properties of these bifunctional molecules. In fact, a variety of other chemical entities and molecular glues have been developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. R&D efforts in this field are being supported by novel DNA-encoded libraries and other versatile bioinformatics tools, which are enabling efficient hit discovery and characterization of potential therapeutic leads. So far, investments worth over USD 3.5 billion have been made in this emerging field of research by various private and public investors. In addition, technology developers with expertise in targeted protein degradation are known to have been involved in several big licensing deals. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Interestingly, several big pharma players are also actively evaluating protein degraders. Although there are no approved protein degrader-based drugs / therapy products in the market yet, we can expect targeted protein degradation to become a major therapeutic modality in the coming decade.
The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030' report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid term and long term.
Chapter 3 is an introductory chapter that highlights important concepts related to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges related to the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.
Chapter 4 includes information on more than 85 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phases of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), types of therapies (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
Chapter 5 features elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
Chapter 6 provides a detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders. The analysis highlights the key trends associated with these clinical studies across various parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
Chapter 7 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
Chapter 8 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain in the period 2014 - 2019. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 9 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
Chapter 10 features a comprehensive market forecast, highlighting the future potential of novel technologies designed for the development of targeted protein degraders till 2030, based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific).
Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market.
Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.